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and other biotransformation genes in male mice using a dextran sulfate sodium (DSS)-induced colitis
model. Several P450 isoforms, including CYP1A, CYP2B, CYP2C, and CYP3A, were down-
regulated, accompanied by decreases in microsomal metabolism of diclofenac and nifedipine, in the liver
and small intestine. The impact of the colitis on in vivo clearance of oral drugs varied for four different
drugs tested: a small decrease for nifedipine, a relatively large decrease for lovastatin, but no change for
pravastatin, and a large decrease in the absorption of cyclosporine A. To further assess the scope of in-
fluence of gut inflammation on gene expression, we performed genome-wide expression analysis using
RNA-seq, which showed down-regulation of many CYPs, non-CYP phase-I enzymes, phase-II enzymes
and transporters, and up-regulation of many other members of these gene families, in both liver and in-
testine of adult C57BL/6 mice, by DSS-induced colitis. Overall, our results indicate that gut inflammation
suppresses the expression of many P450s and other biotransformation genes in the intestine and liver, and
alters the pharmacokinetics for some but not all drugs, potentially affecting therapeutic efficacy or
causing adverse effects in a drug-specific fashion.
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124 Xiaoyu Fan et al.1. Introduction
The cytochrome P450 (P450) superfamily of monooxygenases
controls the homeostasis of many endogenous compounds and
dictates the biotransformation and disposition of innumerable
drugs and other xenobiotics1,2. The intestine is a major site of
P450 expression3e6. Members of the CYP1, CYP2, CYP3, and
CYP4 gene families are the main contributors to the metabolism of
therapeutic drugs1,2,4,7,8. For many orally administered drugs, the
intestinal P450-mediated metabolism can largely affect their
systemic bioavailability.
The expression and activity of drug-metabolizing P450s can be
affected by many factors, including genetic polymorphisms,
epigenetic modifiers, and non-genetic factors such as age, drug
intake, life style, and disease states, leading to changes in first-
pass metabolism of drugs and their therapeutic efficacy9. It has
been reported that circulating pro-inflammatory cytokines mediate
the downregulation of P450s in infection, inflammation, and
cancer10e12, potentially leading to diseaseedrug interactions.
Specific diseases that may alter P450 expression include steato-
hepatitis13, diabetes14, and inflammatory bowel diseases (IBDs),
which are the subject of this study.
IBDs, which consist of ulcerative colitis and Crohn’s disease,
are chronic diseases with acute phase flare-ups. Though the eti-
ology is not fully understood, IBDs are believed to be multifac-
torial diseases resulting from abnormal immunological responses
to certain environmental triggers in genetically predisposed in-
dividuals15. Previous clinical reports and animal studies indicated
that the systemic or local tissue concentrations of certain thera-
peutic drugs, such as cyclosporine A (CsA), 5-aminosalicylic acid,
and metronidazole, were different in subjects with colitis,
compared to those without colitis, and the efficacy of anti-IBD
drugs also varied among patients16e19. However, the status of
drug-metabolism enzymes, a major factor in diseaseedrug in-
teractions, has not been fully examined in IBD patients.
The dextran sulfate sodium (DSS)-induced colitis models in
mice and rats have been widely used as animal models of IBD,
due to their similarities to human ulcerative colitis in etiology,
pathology, pathogenesis and therapeutic responses20. DSS, a
synthetic anionic polymer, is administered to experimental ani-
mals through drinking water; it is minimally absorbed when
passing through the gastrointestinal tract, leading to accumulation
in the colon, where it impairs the tight junctions between colo-
nocytes and initiates colitis20,21. DSS-induced damage, which
involves the mucosa, submucosa and muscularis mucosa of the
colon, is characterized by ulcers, mucosal edema, goblet cell loss,
crypt distortion, abscesses, infiltration of neutrophils, macro-
phages, plasma cells and lymphocytes, and increased production
of pro-inflammatory cytokines, such as TNF-a20. Previous studies
demonstrated that several hepatic P450 enzymes were down-
regulated in a DSS-induced colitis mouse model22e24. However,
the impact of DSS-induced colitis on the expression of intestinal
P450s is less well defined, and its effects on the pharmacokinetics
of oral drugs are unclear.
In the present study, we have examined the expression and
function of some of the major intestinal drug-metabolizing P450
enzymes, including CYP1A, CYP2B, CYP2C, and CYP3A, in the
DSS-induced colitis mousemodel.We showed that the in vivo impact
of DSS-induced colitis on the pharmacokinetics of oral drugs may be
different for different drugs. We further demonstrated that the colitis
condition affected the expression of a wide range of other genes
important for drug disposition in the liver and intestine, includingmany CYPs, other (non-CYP) phase I biotransformation enzymes,
phase II biotransformation enzymes, and drug transporters.
2. Materials and methods
2.1. Chemicals and reagents
DSS was purchased from Affymetrix (Cleveland, OH, USA).
Nifedipine (NFP, purity98%), oxidized NFP (NFPO,
purity95%), nitrendipine (purity95%), diclofenac (DCF) so-
dium salt, dimethyl sulfoxide (DMSO), Tween 80, b-nicotinamide
adenine dinucleotide phosphate, and reduced tetra (cyclohexyl
ammonium) salt (NADPH) (purity97%) were from
SigmaeAldrich (St. Louis, MO, USA). CsA (purity99%),
cyclosporine D (purity95%), 40-OH-DCF-13C6, 40-OH-DCF, 5-
OH-DCF, lovastatin hydroxy acid (LVA, purity95%), and sim-
vastatin hydroxy acid sodium salt (SVA, purity95%) were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Lovastatin (LVS, purity98%) and pravastatin sodium salt (PVS,
purity98%) were purchased from Cayman Chemical (Ann
Arbor, MI, USA). The solvents (acetonitrile, methanol and water)
for high-performance liquid chromatography (HPLC) were from
Thermo Fisher Scientific (Fisher Scientific, Houston, TX, USA).
2.2. Animals and treatments
Male C57BL/6 mice and intestinal epithelium-Cpr-null (IECN)
mice25 (8e12-week old) were studied. Mice were housed under
12-h darkelight cycle and provided food and water ad libitum. To
induce experimental colitis, mice were given 2.5% DSS (w/v) in
drinking water for 7 days; mice in the control group were given
drinking water alone. Body weight, liquid intake, physical activity,
and occurrence of rectal bleeding were monitored daily. Colon
length (from the end of cecum to the anus) was measured on Day
7 of DSS treatment, when mice were sacrificed. For determination
of in vivo drug clearance, mice from DSS-treated and control
groups were treated once, via oral gavage, with 10 mg/kg NFP
[prepared in 10% ethanol, 10% Tween 80, and 80% phosphate-
buffered saline (PBS)]25, 25 mg/kg LVS (prepared in 10%
DMSO, 20% Tween 80, and 70% PBS)26, 50 mg/kg PVS sodium
salt (prepared in PBS), or 10 mg/kg CsA (prepared in 10%
ethanol, 10% Tween 80, and 80% PBS)27, on Day 7. All pro-
cedures involving animals were approved by the Institutional
Animal Care and Use Committees of the Wadsworth Center and
the University of Arizona.
2.3. Preparation of microsomes
Intestinal microsomes were prepared, as described25, from iso-
lated intestinal epithelial enterocytes combined from 2 to 3 mice.
Liver from individual mouse was used for the preparation of he-
patic microsomes, using published procedures28. Protein concen-
tration was determined with the BCA protein assay, using bovine
serum albumin as a standard.
2.4. Immunoblot analysis
Intestinal microsomal proteins (15 mg) were separated on 10%
NuPAGE Bis-Tris gels (Life Technologies, Grand Island, NY,
USA), and then transferred to nitrocellulose membranes, which
were incubated in 5% non-fat milk before the addition of primary
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CYP1A (Millipore, San Diego, CA, USA), rabbit polyclonal
anti-CYP2B (BD Gentest, Woburn, MA, USA)25, goat polyclonal
anti-CYP2C (BD Gentest)25, and rabbit polyclonal anti-CYP3A
(Abcam, Cambridge, MA, USA)29 were used. Rabbit anti-cal-
nexin30 (Abcam) was used for the detection of calnexin, as a
loading control. Peroxidase-conjugated goat anti-rabbit IgG or
rabbit anti-goat IgG (SigmaeAldrich) was used as the secondary
antibody. Immunoreactive bands were visualized with the ECL
Chemiluminescence kit (GE Healthcare, Piscataway, NJ, USA),
and quantified using a ChemiDoc XRS1 System (Bio-Rad, Her-
cules, CA, USA).
2.5. In vitro assays of diclofenac and nifedipine metabolism
DCF metabolism was assayed as described31. Hepatic or intestinal
microsomes (0.1 mg) were incubated with 100 mmol/L DCF in a
reaction mixture containing 0.1 mol/L potassium phosphate buffer
(pH 7.4), 1.0 mmol/L NADPH, and 3 mmol/L MgCl2, in a final
volume of 200 mL. The reaction was initiated by adding NADPH
into the reaction mixture, followed by a 30-min incubation at
37 C. For the control groups, NADPH was omitted. The reaction
was terminated by adding 400 mL of ice-cold acetonitrile. The
internal standard 40-OH-DCF-13C6 (10 mL at 4 ng/mL) was added
for monitoring extraction efficiency for 40-OH-DCF and 5-OH-
DCF. The mixture was vortexed for 1 min, before centrifugation at
1500g for 10 min; the supernatant was collected and spun again
for another 10 min. The supernatant was subjected to solid-phase
extraction (SPE) using ISOLUTE C18 cartridges (Biotage, Char-
lottesville, VA, USA) before LC/MS analysis.
NFP metabolism was assayed as described previously25; the
conditions and procedures used were the same as described above
for the DCF assay, except that NFP was added at 25 mmol/L, and
the incubation period was 10 min. Nitrendipine (100 pmol) was
added as the internal standard for the detection of the reaction
product, NFPO.
Quantitative analysis of 40-OH-DCF, 5-OH-DCF and NFPO
was performed using a LCeMS/MS system consisting of a SCIEX
Q-Trap 6500 þ mass spectrometer (AB SCIEX, Framingham,
MA, USA), an Infinity II Series model 1290 ultra-performance LC
system (Agilent, Santa Clara, CA, USA), and an Agilent ZOR-
BAX Eclipse Plus C18 column (2.1 mm  50 mm, 1.8 mm). The
assay conditions were modified from previously published pro-
tocols31,32, as described in Supporting Information.
2.6. Pharmacokinetic analysis
Blood samples were collected from the tail vein at 10, 30 min, 1,
2, 4, and 10 h after drug treatment, using heparinized capillary
tubes (Thermo Fisher Scientific), and plasma was stored at
80 C until use. The LCeMS/MS system described above was
used for determination of NFP, LVA, PVS, and CsA. The condi-
tions for sample processing and LCeMS analysis were adapted
from previously published protocols26,32,33, as described in
Supporting Information.
2.7. RNA extraction, RNA-sequencing and quantitative real-
time polymerase chain reaction
Total RNA was isolated from intestinal epithelium, colonic
epithelium, and liver using TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA), as described34, and then further purified to removepossible DSS contamination using lithium chloride as a precipi-
tant35. RNA purity and quality were examined with bioanalyzer
and concentration of total RNA was determined with Nanodrop
(Thermo Fisher Scientific). Total RNA (2 mg) was used for first-
strand cDNA synthesis using SuperScript III First-Strand Syn-
thesis System (Invitrogen). Quantitative real-time polymerase
chain reaction (RT-PCR) was performed as described36. The
primers used are listed in Supporting Information Table S1.
Transcripts for the ribosomal phosphoprotein 36B4 was also
measured and used for data normalization.
For RNA-seq analysis, RNAs extracted from the liver and
proximal small intestinal epithelium were further treated with
DNase (Qiagen, Germantown, MD, USA). Samples with RNA
integrity (RIN) scores above 7.2 were used for RNA-seq. RNA
sequencing was performed by Novogene (Sacramento, CA, USA).
Insert size of 250e300 bp was used for cDNA library preparation.
Libraries were sequenced on the Illumina platform for 150-bp
paired-end reads. Reference genome and annotation files were
downloaded from Ensembl, and RNA-seq data were aligned to the
reference genome using the Spliced Transcripts Alignment to a
Reference (STAR) software37. HTSeq was used to obtain read
counts of the mapped genes, and the DESeq2 package was used
for differential expression analysis. ClusterProfiler and KEGG
database were used for enrichment pathway analysis38,39. P values
were adjusted by the Benjamini & Hochberg method40, with
P < 0.05 as the threshold for significantly differential expression.
2.8. Data analysis
Pharmacokinetic (PK) parameters were calculated using PK solver
(Microsoft, Redmond, WA, USA), by assuming a non-
compartmental model. Two-way analysis of variance (ANOVA),
followed by a post-hoc test for pairwise comparisons, or Student’s
t-test, was performed using GraphPad Prism (GraphPad Software,
La Jolla, CA, USA). P values < 0.05 was considered statistically
significant.
3. Results
3.1. Induction of colitis in mice
The DSS-induced colitis model displayed the expected signs of
colon injury and inflammation. No difference was observed in
water intake between DSS group and control group. Symptoms of
colitis started to display from Day 5, including body weight loss,
rectal bleeding, and diarrhea. In the DSS-treated group, body
weight was 85.0% of that on Day 0 after seven-day treatment,
which was significantly decreased compared to the control group
with body weight at 103% of that on Day 0 (Fig. 1A). Colon was
remarkably shortened, by w40% (Fig. 1B), in DSS-treated mice
compared to control mice. Colon inflammation was further sub-
stantiated by significantly elevated mRNA expression levels of IL-
1b, IL-6, and TNF-a, by 152-, 33-, and 9-fold, respectively, in the
DSS-treated mice, compared to control mice (Fig. 1C).
3.2. Impact of DSS-induced colitis on intestinal P450
expression
Consistent with previous reports that hepatic P450s were down-
regulated by DSS treatment22e24, we confirmed that the DSS-
induced colitis was associated with significantly decreased
Figure 1 Induction of colitis in mice by DSS treatment. Mice (2e3-month old, male) were treated with 2.5% DSS in drinking water or water
alone for seven days. (A) Body weight is shown as percentage of initial body weight during treatment with water or 2.5% DSS. (B) Colon length
was measured at the end of treatment on Day 7. (C) Expression of IL-1b, IL-6, and TNF-a mRNAwas determined by RT-PCR as described in
Section Materials and Methods. The relative expression levels were determined by normalizing to 36B4 and are shown in arbitrary units with
levels of the control group set to 1. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to control (water alone) group; means  SD,
n Z 4, Student’s t-test.
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Cyp3a11 in the liver (Fig. 2A). Similar to what was observed in
the liver, intestinal Cyp1a1, Cyp2b10, Cyp2c29, and
Cyp3a11 mRNA expression levels, determined for the proximalFigure 2 Relative expression levels of hepatic and intestinal P450s. Mice
or water alone for seven days. (A) and (B) Effects of DSS treatment on P
intestinal (SI) epithelium were collected on Day 7 for RNA isolation and ge
Materials and Methods; the relative expression levels were determined by n
control (water alone) group set to 1. **P < 0.01, ***P < 0.001, ****P < 0.0
test. (C) Effects of DSS treatment on P450 protein expression in small intes
and immunoblot analysis. Microsomal samples, each prepared from poole
protein per lane), using anti-CYP1A, anti-CYP2B, anti-CYP2C, anti-CY
Section Materials and Methods. Left, representative immunoblots. Right,
and are shown in arbitrary units, with levels of the control (water alone) gr
for quantitative analysis. *P < 0.05 compared with control group; meanssegment of small intestine, were downregulated after seven days
of treatment with DSS, by 3- to 22-fold (Fig. 2B), compared to
control mice. Levels of intestinal microsomal CYP2B and CYP2C
proteins, determined for the epithelium of the entire small(2e3-month old, male) were treated with 2.5% DSS in drinking water
450 mRNA expression in liver (A) and intestine (B). Liver and small
ne expression analysis. RT-PCR was performed as described in Section
ormalizing to 36B4 and are shown in arbitrary units, with levels of the
001 compared with control group; means  SD, nZ 7e8, Student’s t-
tine. SI epithelium were collected on Day 7 for microsome preparation
d SI epithelium from 2 to 3 mice, were analyzed in duplicates (15 mg
P3A, and anti-calnexin (loading control) antibodies, as described in
relative expression levels were determined by normalizing to calnexin
oup set to 1. Data from three different microsomal samples were used
 SD, n Z 3, Student’s t-test.
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decrease also for CYP1A and CYP3A (Fig. 2C).
3.3. Impact of DSS-induced colitis on P450-mediated drug
metabolism in vitro
DCF was first utilized as a probe substrate for studying CYP2C
and CYP3A activities in hepatic and intestinal microsomes pre-
pared from mice that have been treated with DSS in drinking
water (or water alone as a control) for 7 days. The rates of for-
mation of 40-OH-DCF (known metabolite by CYP2C) and 5-OH-
DCF (known metabolite by CYP3A) were 23% and 27%,
respectively, lower in hepatic microsomes (Fig. 3A), and 58% and
64%, respectively, lower in intestinal microsomes (Fig. 3B), of
DSS-treated mice than in control mice. Similarly, the rates of
formation of NFPO from NFP (another CYP3A substrate) were
22% lower in hepatic microsomes, and 44% lower in intestinal
microsomes, of DSS-treated mice than in control mice (Fig. 3C).
3.4. Impact of DSS-induced colitis on in vivo clearance of drugs
Several probe drugs were used to study the impact of DSS-
induced colitis on their in vivo clearance. The plasma levels of
NFP were higher in mice exposed to DSS for 7 days than in
control mice at 2, 4, and 10 h after a single oral dose of NFP at
10 mg/kg (Fig. 4A). The calculated total NFP exposure (AUC0et)
was significantly higher in mice with colitis than in control mice
(Table 1), and the apparent clearance (CL/F ) of NFP was slower
in DSS-treated mice than in control mice. The plasma levels of
LVA, the major circulating form of the pro-drug LVS in mice,
were significantly higher in mice with colitis than in control mice
after a single oral dose of LVS at 25 mg/kg (Fig. 4B). The
calculated values for Cmax and AUC0et were 2.0- and 2.4-fold
higher, respectively, and CL/F was 53% lower, in DSS-treated
mice compared to control mice (Table 1). In contrast, no
obvious difference in plasma level of PVS was observed between
DSS- and water-treated groups after a single oral dose of PVS at
50 mg/kg (Fig. 4C). The calculated PK parameters for PVS did not
show significant differences between the two groups of mice
(Table 1).Figure 3 In vitro metabolism of diclofenac and nifedipine by hepatic and
2.5% DSS in drinking water or water alone for seven days. Liver and sm
Microsomal proteins (0.1 mg) were incubated with 100 mmol/L DCF (A an
potassium phosphate buffer (pH 7.4), 1.0 mmol/L NADPH, and 3.0 mmol
incubation and 10 min for NFP incubation. Metabolites were determined
microsomal sample was prepared from pooled tissues from 2 to 3 mice and
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to controThe effects of colitis on drug clearance were also studied for
CsA, a substrate for both CYP3A and P-glycoprotein, and a drug
with beneficial therapeutic effects in patients with severe ulcera-
tive colitis41,42. Contrary to the observed effects of colitis on the
clearance of NFP and LVS, the plasma concentration of CsA was
significantly lower in DSS-treated mice than in control mice, after
a single oral dose of CsA at 10 mg/kg (Fig. 5). Cmax and AUC0et
values were 60% and 50%, respectively, lower in DSS-treated
mice than in water-treated mice (Table 2), despite the decreased
P450 expression in the DSS-treated group.
The effects of colitis on CsA clearance were also examined in
the intestinal epithelium-Cpr-null (IECN) mice, in which intesti-
nal microsomal P450 activity is abolished due to the ablation of
the Cpr gene in enterocytes25. Plasma levels of CsA were much
higher in IECN mice than in wild-type (WT) mice, in both DSS-
treated or control groups, reflecting the important role of intestinal
P450 in CsA clearance (Fig. 5). Nevertheless, colitis caused an
(IE-P450-independent) decrease (over the corresponding water
control group) in plasma CsA levels (Fig. 5) and calculated Cmax
(by 28%) and AUC (by 33%) values (Table 2), in the IECN mice.3.5. Global gene expression changes in the liver and intestine of
mice with DSS-induced colitis
To explore more broadly the impact of DSS-induced colitis on
gene expression, RNA sequencing analysis was performed for
both liver and proximal intestine, to compare gene expression
changes between control mice and mice that have been treated
with DSS for 7 days. Approximately 47e54 million (liver) and
46e51 million (intestine) total clean reads were generated for
analysis. The uniquely mapping rates were 84.3%e88.5% for liver
and 88.8%e90.1% for intestine. Differential expression analysis
revealed that, with Padj<0.05 as the criterion for significant
changes, 1057 genes were up-regulated and 1280 genes were
down-regulated in the liver; whereas, 351 genes were up-regulated
and 373 genes were down-regulated in the proximal small intes-
tine (Supporting Information Fig. S1).
Four of the top five down-regulated hepatic genes (based on
fold-change), Ces2c (7.3-fold), Cyp2c55 (7.3-fold), Ces2b (7.2-
fold) and Cyp2b10 (4.9-fold), encode drug-processing enzymes;intestinal microsomes. Mice (2e3-month old, male) were treated with
all intestine were collected on Day 7 for preparation of microsomes.
d B) or 25 mmol/L NFP (C) in reaction mixtures containing 0.1 mol/L
/L MgCl2, in a final volume of 200 mL, at 37
C for 30 min for DCF
using LCeMS as described in Section Materials and Methods. Each
three different microsomal samples were used for rate determination.
l (water) group; means  SD, n Z 4, Student’s t-test.
Figure 4 In vivo clearance of nifedipine, lovastatin, and pravastatin in mice with or without DSS treatment. Plasma levels of NFP (A), LVA (B),
and PVS (C) were analyzed at 10 min, 30 min, 1, 2, 4, and 10 h after a single dose of drug administration (at 10, 25, or 50 mg/kg, for NFP, LVS,
and PVS, respectively, by oral gavage) in mice (2e3-month-old, male) pretreated with DSS in drinking water or water alone for 7 days.
*P < 0.05, **P < 0.01 compared to control (water) group; means  SD, n Z 4e8, Student’s t-test.
Table 1 Pharmacokinetic parameters for orally administered nifedipine, lovastatin, and pravastatin in control and DSS-treated mice.
Group Drug Tmax (h) Cmax (mg/mL) t1/2 (h) AUC0et (mg/mL$h) CL/F (L/kg/h)
Water NFP 0.52  0.23 3.30  0.56 2.02  0.55 9.89  2.14 1.02  0.21
DSS NFP 0.52  0.23 3.20  0.58 3.73  2.13* 14.0  3.2** 0.65  0.23**
Water LVS 0.37  0.18 0.43  0.14 1.34  0.68 0.66  0.09 37.7  5.8
DSS LVS 0.43  0.15 0.99  0.31** 1.41  0.12 1.60  0.75* 17.8  6.6***
Water PVS 0.25  0.17 0.22  0.09 1.82  1.10 0.22  0.06 202  53
DSS PVS 0.17  0.01 0.10  0.04 3.32  1.34 0.17  0.10 290  123
Data from Fig. 4 were used for determination of pharmacokinetic parameters. Adult male C57BL/6 mice were treated with DSS in drinking water
for 7 days at 2.5% (w/v), or with water alone. On Day 7, mice were given NFP, LVS, and PVS at 10, 25, and 50 mg/kg, respectively, by oral gavage.
Values represent means  SD (n Z 5e8). LVS was measured as LVA.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to corresponding water group (Student’s t-test).
Figure 5 In vivo clearance of cyclosporine A in WT and IECN
mice with or without DSS treatment. Plasma levels of CsA were
analyzed at 10, 30 min, 1, 2, 4, and 10 h after a single dose of CsA at
10 mg/kg by oral gavage in WT and IECN mice (2e3-month old,
male) pretreated with DSS in drinking water or water alone for 7 days.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to corresponding
control (water) group; #P < 0.05, ##P < 0.01, ###P < 0.001,
####P < 0.0001 compared to corresponding WT group; means  SD,
n Z 6e10, two-way ANOVA with Tukey’s multiple comparison test.
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factor-binding protein 3. Two of the top five down-regulated in-
testinal genes were also related to drug metabolism, Cyp2c29 (4.9-
fold) and Ces2b (2.6-fold); the others were Igfbp3 (4.9-fold),
Axin2 (3.4-fold), which is a downstream target of the Wnt/b-cat-
enin pathway43, and Dnase1l3 (2.8-fold), which regulates cytokine
secretion44. The colitis-induced decreases in P450 expression that
was demonstrated using PCR (Fig. 2) were also confirmed by the
RNA-seq analysis (Fig. 6).
Fold-change-vs-abundance data (M-A plot) for all detected
transcripts in various subgroups are shown graphically in Fig. 6.
The differentially expressed genes (with change-fold greater than
1.5, abundance greater than 100 counts, and adjusted P value less
than 0.05) that are involved in drug metabolism and transport are
selected for presentation in Table 3, with the total number of
changed genes in the liver (123) included 25 CYPs (7 up and 18
down), 23 Non-CYP phase I enzymes (1 up and 22 down), 27
phase II enzymes (2 up and 25 down), 9 ATP-binding cassette
(ABC) efflux transporters (9 down), and 39 solute carriers (SLC)/
solute carrier organic anion (SLCO) uptake transporters (21 up
and 18 down). The total number of changed genes in the proximal
intestine (26) included 8 CYPs (2 up and 6 down), 6 Non-CYP
phase I enzymes (3 up and 3 down), 4 phase II enzymes (2 up
and 2 down), 1 ABC efflux transporters (1 up), and 7 SLC/SLCO
uptake transporters (4 up and 3 down). The non-CYP phase I
enzymes queried included alcohol dehydrogenases (ADHs),
aldehyde dehydrogenases (ALDHs), aldo-keto reductases (AKRs),
carboxylesterases (CESs), dehydrogenase/reductases (DHRs),
dihydropyrimidinase (DPYD), short-chain dehydrogenase/re-
ductases (SDRs), xanthine dehydrogenase (XDH), arylacetamide
deacetylase (AADAC), elastases (CELAs), epoxide hydrolases(EPHXs), esterase (ESD), flavin-containing monooxygenases
(FMOs), prolidase (PEPD), paraoxonases (PONs), sulfite oxidase
(SUOX), carbonyl reductases (CBRs), NAD(P)H: quinone oxi-
doreductases (NQOs), alternative oxidases (AOXs), monoamine
oxidases (MAOs), and P450 oxidoreductase (POR). Phase II
Table 2 Pharmacokinetic parameters for orally administered cyclosporine A in control and DSS-treated WT and IECN mice.
Group Tmax (h) Cmax (mg/mL) t1/2 (h) AUC0et (mg/mL$h) CL/F (L/kg/h)
Water-WT 1.50  0.55 0.63  0.12 5.95  1.45 3.35  0.51 2.02  0.40
Water-IECN 1.70  0.48 1.30  0.24#### 10.2  5.3 8.60  1.33#### 0.60  0.18#
DSS-WT 1.50  0.77 0.25  0.09* 6.10  1.85 1.67  0.48* 4.86  1.70****
DSS-IECN 1.71  0.49 0.94  0.30*,#### 6.28  3.72 5.77  1.53***,#### 1.31  0.68####
Data from Fig. 5 were used for determination of pharmacokinetic parameters. Adult male WT and IECN mice were treated with DSS in drinking
water at 2.5% (w/v), or with water alone, for 7 days. On Day 7, mice were given CsA at 10 mg/kg by oral gavage. Values represent means  SD
(n Z 6e10).
*P < 0.05, ***P < 0.001, ****P < 0.0001 compared to corresponding water group; #P < 0.05, ####P < 0.0001 compared to corresponding WT group
(Two-way ANOVA followed by Tukey’s test).
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glutathione S-transferases (GSTs), microsomal glutathione S-
transferases (MGSTs), sulfotransferase (SULTs), methyl-
transferases (HNMT, COMT, TPMT and AS3MT), acyl-
transferases (BAAT, GLYAT and NATs), and enzymes for co-
substrates of phase II enzymes (GCLC, GCLM, UGDH, UGP2,
PAPSSs and MATs). The transporters were divided as ABC efflux
transporters and SLC/SLCO uptake transporters.
Enrichment analysis (Supporting Information Fig. S2, for top
20 changed pathways) indicated that drug-metabolism-related
pathways are among the most significantly changed by colitis,
based on adjusted P value. The top five pathways affected by DSS
treatment in liver were metabolic pathways (320 genes differen-
tially expressed), metabolism of xenobiotics by P450s (39 genes
differentially expressed), complement and coagulation cascades
(39 genes differentially expressed), drug metabolism (41 genes
differentially expressed), and citrate cycle (21 genes differently
expressed). The top five pathways affected by DSS in the small
intestine were drug metabolism (16 genes differentially
expressed), metabolism of xenobiotic by P450s (14 genes differ-
entially expressed), linoleic acid metabolism (10 genes differen-
tially expressed), complement and coagulation cascades (13 genes
differentially expressed), and osteoclast differentiation (16 genes
differentially expressed).
4. Discussion
We have shown evidence for down-regulation of several drug-
metabolizing CYPs in the small intestine, in addition to the liver,
by DSS-induced colitis in the present study. These CYPs, partic-
ularly CYP2C and CYP3A, are among the most important drug-
metabolizing P450 enzymes, as they collectively metabolize a
large fraction of all prescribed drugs45. CYP3A and CYP2C are
also the most predominant P450 isoforms in the intestine2,34. The
effects of colitis on CYP expression (Fig. 2) were further sup-
ported by data on significant decreases in microsomal activities
toward probe substrates, NFP (for CYP3A) and DCF (for CYP2C
and CYP3A, Fig. 3).
Our data on colitis-induced downregulation of P450 expres-
sion confirm the findings of a previous report, where treatment of
male C57BL/6 mice with 5% DSS (we used 2.5%) for 7 days
caused downregulation of CYP3A in the upper small intestine at
mRNA and protein levels23. Two other studies have examined
effects of DSS on intestinal P450 expression; their findings
appear to differ from ours and those of Kawauchi and co-
workers23. In one, treatment of male ICR mice with 3.5% DSS for
10 days did not change microsomal CYP3A level in the smallintestine24. In the other, treatment of male SpragueeDawley rats
with 3% DSS for 7 days did not cause a decrease in CYP activity
toward NFP in intestinal microsomes46. Several reasons might
account for these apparent discrepancies, including possible
species or mouse strain differences in the DSS-induced inflam-
matory response, the different concentrations and sources of DSS
used, and the differences in the specific parts of the intestine that
were analyzed, which may show differing extent of response to
inflammation. Notably, our study provides, for the first time, data
on comprehensive analysis of colitis-induced changes in the
expression of various drug-metabolism and disposition-related
genes in the liver and intestine, including not only CYPs, but
also non-CYP phase I enzymes, phase II enzymes, and drug
transporters.
Possible mechanisms of the colitis-induced intestinal CYP
down-regulation remain to be determined. In that regard, previous
work had indicated that, in the liver of DSS-treated mice, an in-
crease in hepatocyte and serum cytokines might have led to an
increased NF-kB nuclear translocation, decreased PXR and CAR
nuclear translocation and mRNA expression, and consequent
downregulation of P450 expression23,24,47. Nevertheless, DSS
treatment has not been associated with histological inflammation
or increases in cytokine levels in the small intestine. Hence,
studies on whether enterocyte cytokine level is elevated, and the
NF-kB pathway is activated, are needed to determine whether the
same mechanisms occur in the intestine. Additionally, a reduction
in FXR activation, which can lead to decreased activation of PXR
and downregulated CYP3A expression in the intestine, may occur,
due to DSS-induced decrease in bile acid levels23. It may be
necessary to examine the time course of changes in the expression
of the various regulatory molecules during disease onset and
progression, as well as during recovery following termination of
the DSS treatment. In that connection, it has been reported that the
extent of post-DSS recovery may differ for different hepatic P450
transcripts in mice48 and for hepatic, renal, or intestinal micro-
somal P450 activities in rats46.
To investigate whether the downregulation of hepatic and in-
testinal P450s has an impact on in vivo drug clearance, four probe
drugs, NFP, LVS, PVS, and CsA, belonging to different Bio-
pharmaceutics Classification System (BCS)/Biopharmaceutical
Drug Disposition Classification System (BDDCS) categories,
were studied49. NFP is a BCS I/BDDCS I drug, with relatively
high solubility, high permeability, high metabolism, but minimal
involvement of transporters in absorption25,49. Mice with colitis
displayed slower systemic clearance of NFP, compared to control
mice [as indicated by greater total exposure (AUC), longer half-
life, and slower apparent clearance (CL/F ), Fig. 4 and Table 1),
Figure 6 Differential expression of genes between mice with or without colitis analyzed using RNA-seq. Mice (2e3-month old, male) were
treated with 2.5% of DSS dissolved in drinking water or water alone for seven days. Hepatic and SI total RNA was used for RNA-sequencing
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enzyme CYP3A in liver and intestine.
LVS, a BCS II/BDDCS II drug, is rapidly hydrolyzed to
become LVA, its active form50 and the major circulating form of
the drug in mice51. LVS and LVA are both CYP3A substrates52,53,
though they are also metabolized to a lesser extent by other en-
zymes, such as CYP2C and UGTs26,54. Unlike NFP, LVS ab-
sorption involves several transporters54, some of which, including
MRP2, MDR1, and BSEP, are suppressed in the liver by DSS
treatment23. The pharmacokinetics of plasma LVA is impacted by
colitis in similar ways as for NFP, with an increase in AUC and a
decrease in CL/F, except that, contrary to the result for NFP, the
Cmax value for LVA is also increased, whereas plasma half-life
was not changed (Fig. 4 and Table 1). The reason for this subtle
difference between NFP and LVS/LVA is unclear; but it may be
partly related to the effects of colitis on other drug-metabolizing
enzymes and drug transporters, as suggested by the subsequent
RNA-seq analysis (Table 3) and by previous studies of DSS effects
on hepatic transporters23.
PVS, a BCS III/BDDCS III drug, with high solubility and low
permeability, undergoes little P450-mediated metabolism. Its
disposition involves several transporters, including OATP1B1,
OATP2B1, OATP1A2, OAT1, OAT3, and MDR154,55. In DSS-
treated mice, there is no evident change in the various PK pa-
rameters for PVS, compared to water-treated mice (Fig. 4 and
Table 1), which is consistent with the lack of P450 involvement in
PVS metabolism, and also suggests that any changes in transporter
expression was insufficient to alter the disposition of PVS.
Interestingly, the effect of colitis on the pharmacokinetics of
CsA, another BCS II/BDDCS II drug, was unexpected. When
taken orally, CsA undergoes first-pass extraction by CYP3A in the
intestine and liver56,57. However, colitis mice showed dramatic
decreases in plasma CsA levels after a single oral dose, compared
to water-alone control mice. The role of intestinal P450-mediated
CsA metabolism on CsA bioavailability was confirmed by
comparing WT and IECN mice (Fig. 5). Nevertheless, both WT
and IECN mice showed colitis-induced decrease in Cmax and
AUC, but not in t1/2, which suggests colitis-associated changes in
CsA absorption (Fig. 5 and Table 2). In that regard, the gastro-
intestinal absorption of CsA can be influenced by many factors,
including bile acids in the gut, which can assist in the dissolution
of CsA and increase its absorption58. Bile acid levels in the small
intestinal lumen were reported to be lower (by 2-fold) in DSS-
treated mice than in water-treated mice23, which might have at
least partially contributed to the apparent, colitis-associated
decrease in CsA absorption observed in this study. CsA absorp-
tion may also be impeded by diarrhea59, which occurs in DSS-
induced colitis mice. Thus, the anticipated effects of a decreased
CYP expression on drug disposition is overshadowed by upstream
decreases in drug absorption that might have resulted from a
multitude of disease-associated changes, including reductions in
bile acid levels and other pathological conditions.analysis. M-A (log ratio-mean average) plots for hepatic (A) or proximal S
enzymes, and transporters are shown. Log2 fold-changes (DSS/water) are p
to five most highly expressed transcripts (based on counts, in purple box) t
(based on fold change, in orange box), filtered by jlog2 (fold change)j >
notated. CYPs that were found to be changed in mRNA expression using R
expression analysis and pathway analysis are shown in Supporting InformNotably, the effect of DSS-induced colitis on CsA level
was also examined in the study of Kawauchi and co-
workers23. CsA was given orally to control and DSS-treated
mice at 1 mg/kg (10 mg/kg was in our study), and whole-
blood CsA levels were determined at two time points (30
and 60 min after dosing). Contrary to our finding, they re-
ported higher (by w2-fold) blood CsA levels in DSS-treated
mice than in control mice. The reason for this discrepancy
is unclear, but it might be related to the large difference in
the doses administered between the two studies; it is possible
that, at 1 mg/kg, intestinal absorption was not limiting, and
the effects of a decreased CYP3A expression on CsA dispo-
sition can be demonstrated.
The differing outcomes of colitis on the pharmacokinetics of
the four drugs tested demonstrate that the effects of colitis on
in vivo drug clearance is drug-specific. The reasons for the drug
specificity of the in vivo effects of colitis are complicated and
will be important to study. It may include the differential roles
of the changed P450s in the first-pass extraction of a particular
drug; the role of other phase-I biotransformation enzymes and
phase-II metabolism; the involvement of enterohepatic recir-
culation; and the role of specific transporters in the absorption
or excretion of a given drug. In that regard, the results of our
broad survey, using RNA-seq, indicate widespread effects of
colitis on various groups of drug metabolism and disposition
genes (Fig. 6 and Table 3) and pathways (Supporting Infor-
mation Fig. S2). Notably, though more genes are down-
regulated by colitis, some genes are upregulated, which further
complicates the situation. Validation of these changes at the
protein level, and a comprehensive knowledge of the activities
of each of these changed enzymes or transporters, is necessary
to predict the impact of colitis on the pharmacokinetics of a
specific drug.
IBD patients often experience co-morbidities, such as car-
diovascular diseases and hypercholesterolemia60. Therefore, the
altered pharmacokinetic profiles of anti-hypertensive drugs, such
as NFP, nimodipine, and verapamil, and anti-
hypercholesterolemia drugs, such as LVS and simvastatin,
could impact therapeutic efficacy and potentially cause life-
threatening adverse effects in these patients. Colitis-induced
changes in pharmacokinetics may also directly impact the
safety or efficacy of drugs used in the treatment of IBD, such as
CsA, an immunosuppressive agent, which, in addition to its
common use in organ transplantation and other immune-related
conditions, is also used in ulcerative colitis to delay surgery.
Thus, it is important to consider the effects of colitis on drug
metabolism and disposition when prescribing for IBD patients.
In that regard, given potential species differences between mice
and humans, similar analyses to what has been done in mice
should be conducted for humans, to yield human gene expres-
sion data that can be directly used to build a predictive model
for colitis effects on drug disposition.I (B) mRNA expression of CYPs, non-CYP phase I enzymes, phase II
lotted against averaged read-counts of the two comparison groups. Up
hat are changed, and up to five most increased or decreased transcripts
0.585 (1.5-fold) and Padj <0.05, are highlighted by red dots and an-
T-PCR (Fig. 2) are circled in green. Results of global differential gene
ation Figs. S1 and S2 , respectively.
Table 3 Summary of differentially expressed genes of CYPs, non-CYP phase I enzymes, phase II enzymes, and transporters.
Liver Proximal small intestine
Gene Ensembl ID Fold change
(log2)
Adjusted P-
value
Gene Ensembl ID Fold change
(log2)
Adjusted P-
value
Gene Ensembl ID Fold change
(log2)
Adjusted P-
value
Down-regulated genes
Phase I, CYPs
Cyp2c44 ENSMUSG00000025197 0.61 5.48E-05 Cyp8b1 ENSMUSG00000050445 1.23 1.77E-06 Cyp3a11 ENSMUSG00000056035 0.77 1.36E-02
Cyp2c67 ENSMUSG00000062624 0.63 1.12E-03 Cyp2u1 ENSMUSG00000027983 1.23 5.07E-06 Cyp2b10 ENSMUSG00000030483 0.82 2.74E-03
Cyp2d9 ENSMUSG00000068086 0.68 3.96E-04 Cyp4v3 ENSMUSG00000079057 1.27 2.73E-16 Cyp2c55 ENSMUSG00000025002 1.09 2.39E-03
Cyp3a59 ENSMUSG00000061292 0.69 1.49E-02 Cyp2f2 ENSMUSG00000052974 1.30 1.48E-14 Cyp2c65 ENSMUSG00000067231 1.12 2.91E-10
Cyp1a2 ENSMUSG00000032310 0.75 2.12E-03 Cyp3a11 ENSMUSG00000056035 1.62 5.71E-22 Cyp2c66 ENSMUSG00000067229 1.61 2.84E-10
Cyp2c37 ENSMUSG00000042248 0.92 1.49E-05 Cyp4b1 ENSMUSG00000028713 1.63 9.87E-10 Cyp2c29 ENSMUSG00000003053 2.28 2.68E-18
Cyp2c38 ENSMUSG00000032808 0.97 2.81E-03 Cyp2a5 ENSMUSG00000005547 2.70 4.57E-51
Cyp2c29 ENSMUSG00000003053 0.98 2.13E-06 Cyp4a12b ENSMUSG00000078597 3.05 6.28E-32
Cyp3a25 ENSMUSG00000029630 1.06 1.94E-09 Cyp4a12a ENSMUSG00000066071 3.18 5.09E-54
Phase I, Non-CYP
Aadac ENSMUSG00000027761 1.10 3.95E-18 Ces1f ENSMUSG00000031725 1.21 3.78E-09 Ces2g ENSMUSG00000031877 0.82 1.06E-07
Akr1c19 ENSMUSG00000071551 0.77 9.31E-03 Ces2a ENSMUSG00000055730 1.05 1.57E-16 Ces2b ENSMUSG00000050097 1.36 5.96E-06
Aldh1b1 ENSMUSG00000035561 0.60 2.17E-03 Ces2c ENSMUSG00000061825 2.87 1.48E-11 Fmo1 ENSMUSG00000040181 1.59 3.50E-10
Aldh3a2 ENSMUSG00000010025 2.17 3.97E-45 Ces2e ENSMUSG00000031886 1.44 3.67E-22
Aldh5a1 ENSMUSG00000035936 0.69 1.96E-05 Ces3b ENSMUSG00000062181 1.18 1.15E-18
Aldh7a1 ENSMUSG00000053644 0.65 5.33E-06 Dpyd ENSMUSG00000033308 0.59 1.26E-03
Aldh9a1 ENSMUSG00000026687 0.59 7.45E-05 Ephx1 ENSMUSG00000038776 1.03 1.18E-10
Aox1 ENSMUSG00000063558 0.92 1.65E-08 Ephx2 ENSMUSG00000022040 1.20 4.39E-22
Aox3 ENSMUSG00000064294 0.91 4.28E-10 Maob ENSMUSG00000040147 0.80 3.04E-06
Cela1 ENSMUSG00000023031 1.19 2.30E-06 Nqo2 ENSMUSG00000046949 0.91 6.15E-08
Ces1e ENSMUSG00000061959 1.68 1.15E-27 Suox ENSMUSG00000049858 0.86 1.34E-10
Phase II
Gstk1 ENSMUSG00000029864 0.59 5.30E-05 Ugt2b36 ENSMUSG00000070704 0.87 6.51E-08 Gstm4 ENSMUSG00000027890 0.95 6.82E-05
Gstp1 ENSMUSG00000060803 0.92 2.42E-04 Ugt1a5 ENSMUSG00000089943 0.93 1.58E-04 Gstm3 ENSMUSG00000004038 1.19 4.98E-05
Gstm4 ENSMUSG00000027890 0.93 1.88E-07 Ugt2a3 ENSMUSG00000035780 0.96 3.08E-09
Gstm2 ENSMUSG00000040562 1.14 2.21E-06 Ugt2b35 ENSMUSG00000035811 1.06 1.12E-10
Gstm1 ENSMUSG00000058135 1.14 2.24E-17 Ugt2b5 ENSMUSG00000054630 1.33 1.25E-20
Gstt1 ENSMUSG00000001663 1.21 8.14E-13 Ugt1a9 ENSMUSG00000090175 1.61 1.29E-17
Gstm6 ENSMUSG00000068762 1.32 2.20E-19 Ugt2b1 ENSMUSG00000035836 2.00 1.60E-32
Gstm3 ENSMUSG00000004038 1.74 6.21E-16 Ugt2b38 ENSMUSG00000061906 2.83 3.65E-21
Gstt3 ENSMUSG00000001665 1.88 9.72E-12 Sult1b1 ENSMUSG00000029269 0.70 6.82E-03
Gstt2 ENSMUSG00000033318 1.89 1.66E-17 Gclc ENSMUSG00000032350 0.82 1.29E-08
Gsta4 ENSMUSG00000032348 2.16 1.91E-36 Papss2 ENSMUSG00000024899 1.04 1.53E-05
Gsta2 ENSMUSG00000057933 3.45 4.19E-45 Ugp2 ENSMUSG00000001891 1.42 5.63E-20
Ugt3a1 ENSMUSG00000072664 0.71 3.56E-06
ABC Transporters
Abca2 ENSMUSG00000026944 0.75 3.40E-06 Abcc9 ENSMUSG00000030249 1.02 7.68E-07
Abcb11 ENSMUSG00000027048 0.85 8.91E-11 Abcg5 ENSMUSG00000040505 1.04 3.88E-10
Abca8a ENSMUSG00000041828 0.97 6.72E-06 Abcc3 ENSMUSG00000020865 1.19 6.18E-09
Abcb4 ENSMUSG00000042476 0.98 2.28E-10 Abcd3 ENSMUSG00000028127 1.25 1.15E-14
Abcg8 ENSMUSG00000024254 1.02 5.16E-09
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SLC and SLCO transporters
Slc1a2 ENSMUSG00000005089 0.59 2.89E-04 Slc25a22 ENSMUSG00000019082 0.85 3.27E-07 Slc9a2 ENSMUSG00000026062 0.64 3.44E-02
Slc6a6 ENSMUSG00000030096 0.59 3.45E-03 Slc35g1 ENSMUSG00000044026 0.90 5.12E-05 Slc5a4a ENSMUSG00000020229 1.12 6.46E-09
Slc22a30 ENSMUSG00000052562 0.64 1.33E-04 Slc7a2 ENSMUSG00000031596 0.96 2.98E-05 Slc12a2 ENSMUSG00000024597 1.16 4.27E-05
Slc25a10 ENSMUSG00000025792 0.65 5.07E-05 Slc22a28 ENSMUSG00000063590 0.98 2.20E-04
Slc25a15 ENSMUSG00000031482 0.67 2.80E-06 Slc17a8 ENSMUSG00000019935 1.10 5.62E-04
Slc23a2 ENSMUSG00000027340 0.69 2.01E-02 Slc25a30 ENSMUSG00000022003 1.28 1.83E-02
Slc9a3r2 ENSMUSG00000002504 0.74 5.31E-03 Slc43a3 ENSMUSG00000027074 1.33 1.50E-10
Slc30a10 ENSMUSG00000026614 0.75 7.29E-03 Slc2a2 ENSMUSG00000027690 1.42 4.73E-17
Slc10a1 ENSMUSG00000021135 0.77 1.85E-06 Slc17a4 ENSMUSG00000021336 1.68 1.29E-17
Up-regulated genes
Phase I, CYPs
Cyp2d40 ENSMUSG00000068083 0.66 3.48E-04 Cyp51 ENSMUSG00000001467 0.81 1.12E-07 Cyp2j6 ENSMUSG00000052914 0.83 5.46E-03
Cyp39a1 ENSMUSG00000023963 0.68 1.77E-02 Cyp4a31 ENSMUSG00000028712 1.39 7.22E-05 Cyp2j9 ENSMUSG00000015224 0.96 4.17E-03
Cyp2c70 ENSMUSG00000060613 0.69 2.21E-05 Cyp3a13 ENSMUSG00000029727 1.54 3.07E-28
Cyp17a1 ENSMUSG00000003555 0.75 3.29E-02
Phase I, Non-CYP
Por ENSMUSG00000005514 0.71 2.95E-03 Aldh3b1 ENSMUSG00000024885 0.60 7.08E-05
Adh1 ENSMUSG00000074207 0.65 9.44E-03
Akr1b7 ENSMUSG00000052131 0.67 3.96E-02
Phase II
As3mt ENSMUSG00000003559 0.80 1.41E-06 Papss2 ENSMUSG00000024899 0.70 3.77E-02
Papss1 ENSMUSG00000028032 0.66 1.38E-02 Mgst1 ENSMUSG00000008540 0.87 5.36E-03
ABC Transporters
Abcc6 ENSMUSG00000030834 0.84 1.26E-03
SLC and SLCO transporters
Slc30a1 ENSMUSG00000037434 0.60 7.53E-04 Slc1a4 ENSMUSG00000020142 1.15 1.81E-06 Slc25a28 ENSMUSG00000040414 0.64 6.26E-05
Slc46a3 ENSMUSG00000029650 0.62 5.90E-03 Slc13a3 ENSMUSG00000018459 1.26 2.07E-09 Slc19a2 ENSMUSG00000040918 0.81 4.79E-06
Slc43a1 ENSMUSG00000027075 0.62 2.39E-02 Slc11a2 ENSMUSG00000023030 1.29 3.85E-11 Slc35e3 ENSMUSG00000060181 0.90 1.27E-03
Slc35e3 ENSMUSG00000060181 0.65 3.34E-03 Slc10a2 ENSMUSG00000023073 1.30 7.16E-03 Slc6a3 ENSMUSG00000021609 1.03 6.05E-03
Slc41a1 ENSMUSG00000013275 0.65 1.97E-02 Slc17a9 ENSMUSG00000023393 1.31 4.59E-05
Slc35b1 ENSMUSG00000020873 0.66 7.66E-04 Slc39a14 ENSMUSG00000022094 1.45 5.91E-13
Slc11a1 ENSMUSG00000026177 0.68 3.24E-02 Slc41a2 ENSMUSG00000034591 2.16 2.22E-08
Slc25a19 ENSMUSG00000020744 0.76 7.18E-04 Slc13a5 ENSMUSG00000020805 2.19 2.24E-14
Slc39a1 ENSMUSG00000052310 0.87 4.11E-08 Slc3a1 ENSMUSG00000024131 2.50 6.29E-42
Slc16a12 ENSMUSG00000009378 0.90 2.39E-05 Slc37a1 ENSMUSG00000024036 3.01 8.82E-30
Slc30a5 ENSMUSG00000021629 1.00 4.26E-09
Differential gene expression was analyzed by RNA-seq for hepatic and SI RNA samples from mice with or without colitis, as described in Fig. 6. Genes with normalized readout mean > 100, adjusted P-
value <0.05, jlog2 fold changej >0.585 are presented in various subgroups of drug-metabolizing enzymes and transporters.
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134 Xiaoyu Fan et al.5. Conclusions
In summary, we have examined the impact of gut inflammation
on the expression of intestinal P450 and other biotransformation
enzymes and drug transporters in male mice using a DSS-
induced colitis model. Our results indicate that colitis sup-
presses the expression of many P450s and other biotransfor-
mation genes in the liver and intestine, and alters the
pharmacokinetics for some but not all drugs, potentially
affecting therapeutic efficacy or cause adverse effects in a drug-
specific fashion.
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